Document is current
Any future updates will be listed below
-
Authors
Burnside, Jessica
Cinque, Felice
Sebastiani, Giada
Ramji, Alnoor
Patel, Keyur
Swain, Mark
Saeed, Sahar https://orcid.org/0000-0002-0224-379X
-
Funding
Funding for this research was provided by:
Queen's University (Research Initiation Grant)
Government of Ontario (Ontario Graduate Scholarship)
Fonds de Recherche du Québec - Santé (296306)
Cal Wenzel Family Foundation (Endowed Chair in Hepatology)
- License Information
-
More Information
Article History
Received: 9 October 2024
Accepted: 27 February 2025
First Online: 5 May 2025
Declarations
:
: Sebastiani has acted as speaker for Merck, Gilead, Abbvie, Novo Nordisk, and Pfizer; served as an advisory board member for Pfizer, Merck, Novo Nordisk, and Gilead; and has received unrestricted research funding from Theratechnologies Inc. Swain has served in an advisory role for Ipsen, Novo Nordisk, GSK, Abbott, and Advanz; served as a speaker for Abbott; and has received clinical trial or research support from Gilead, BMS, CymaBay, Intercept, Genfit, Pfizer, Novartis, Astra Zeneca, GSK, Celgene, Novo Nordisk, Axcella Health Inc., Merck, Galectin Therapeutics, Calliditas Therapeutics, Madrigal, AbbVie, Altimmune, Roche, Kowa, Ipsen, Intercept, and 89Bio. Patel has acted as an advisor/consultant—Novo Nordisk, Merck, Resalis; DSMB—Gilead Sciences, Galectin. Saeed has served as an advisory board member for Novo Nordisk. Ramji has acted as an advisor/consultant for Abbvie, Gilead, Intercept/Advanz, Janssen, Novo-Nordisc, and Pfizer and has received grant/research support from Abbvie, Galmed, Gilead, Intercept, Janssen, Merck, Novartis, and Novo-Nordisc.
: The opinions expressed in this manuscript are the authors’ own and do not reflect the views of the Canadian Longitudinal Study on Aging.
